Hippo signaling is a critical player in controlling the growth of several tissues and organs in diverse species. The current model of Hippo signaling postulates a cascade of kinase activity initiated by the MST1/2 kinases in response to external stimuli. This leads to inactivation of the transcriptional coactivators, YAP/TAZ, due to their cytoplasmic retention and degradation that is correlated with YAP/TAZ phosphorylation. In most tissues examined, YAP plays a more dominant role than TAZ. Whether a conserved Hippo pathway is utilized during lung growth and development is unclear. In particular, the regulatory relationship between MST1/2 and YAP/TAZ in the lung remains controversial. By employing the Shh-Cre mouse line to efficiently inactivate genes in the lung epithelium, we show that loss of MST1/2 kinases in the epithelium can lead to neonatal lethality caused by lung defects. This is manifested by perturbation of lung epithelial cell proliferation and differentiation. These phenotypes are more severe than those produced by Nkx2.1-Cre, highlighting the effects of differential Cre activity on phenotypic outcomes. Importantly, expression of YAP targets is upregulated and the ratio of phospho-YAP to total YAP protein levels is reduced in Mst1/2-deficient lungs, all of which are consistent with a negative role of MST1/2 in controlling YAP function. This model gains further support from both in vivo and in vitro studies. Genetic removal of one allele of Yap or one copy of both Yap and Taz rescues neonatal lethality and lung phenotypes due to loss of Mst1/2. Moreover, knockdown of Yap in lung epithelial cell lines restores diminished alveolar marker expression caused by Mst1/2 inactivation. These results demonstrate that MST1/2 inhibit YAP/TAZ activity and establish a conserved MST1/2-YAP axis in coordinating lung growth during development.
Introduction
Hippo signaling plays a central role in tissue development, regeneration and tumor development in several tissues and organs that have been examined (Varelas, 2014) . In contrast, whether the Hippo pathway executes key steps of lung development and physiology and whether aberrant Hippo signaling leads to lung pathology are underexplored (Mahoney et al., 2014; Zhao et al., 2014) . The available mouse Cre lines that direct lung expression (Rawlins and Perl, 2012) and conditional alleles of Hippo pathway components would enable studies to provide a more definitive answer to the role of Hippo signaling in the lung. These investigations will also elucidate the molecular mechanisms by which Hippo signaling controls various aspects of lung biology.
The basic framework of Hippo signaling has been established through extensive work in model organisms and cell-based assays (Barry and Camargo, 2013; Gumbiner and Kim, 2014; Halder and Johnson, 2011; Harvey and Hariharan, 2012; Matsui and Lai, 2013; Pan, 2010; Staley and Irvine, 2012; Yu and Guan, 2013) . At the core of the current model of mammalian Hippo signaling is a kinase cascade that controls the activity of the transcriptional coactivator, YAP (Yes-associated protein) (Huang et al., 2005; Sudol, 1994; Sudol et al., 1995) , to govern multiple aspects of cell physiology. In mammals, the STE20-like protein kinases, MST1/2, phosphorylate and activate the large tumor suppressor kinases, LATS1/2 (Chan et al., 2005) . Active LATS phosphorylates YAP (Oka et al., 2008) and YAP phosphorylation is associated with its cytoplasmic sequestration and degradation (Zhao et al., 2010) . Consequently, the transcriptional targets of YAP in the nucleus are not activated. By contrast, when MST1/2 are inactivated in response to external signals (such as low cell density), YAP becomes hypophosphorylated and it is postulated that this form of YAP is enriched in the nucleus and activates Hippo targets in conjunction primarily with the TEA domain family transcription factors, TEAD1-4 (Jacquemin et al., 1996; Ota and Sasaki, 2008; Sawada et al., 2008) .
Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/developmentalbiology This would mediate a diverse array of cellular functions such as cell proliferation, differentiation and death. In this model, loss of MST1/2 is expected to result in a relative reduction in LATS and YAP phosphorylation.
TAZ (transcriptional co-activator with PDZ-binding motif) shares homology with YAP and also functions as a transcriptional co-activator in Hippo signaling. Loss of Taz in mice leads to milder phenotypes than those in Yap knockout mice. Yap-deficient embryos exhibit early lethality at 9.5-10.5 days post-coitus (dpc) (Morin-Kensicki et al., 2006) and conditional inactivation of Yap in various tissues results in defective development or homeostasis (Reginensi et al., 2013; Schlegelmilch et al., 2011; Xin et al., 2011; Zhang et al., 2010) . By contrast, although some Taz-deficient mice die during the perinatal and postnatal period, one-fifth of Taz mutant mice grow to adulthood (Makita et al., 2008) . The major defects in the absence of Taz are renal cysts and emphysematous changes in the lung (Makita et al., 2008) . Thus, while Taz shares functional redundancy with Yap, YAP is the major player in mediating Hippo signaling in most tissues.
Studies in several tissues have uncovered key aspects of Hippo signaling in vivo but context-dependent variations in the interactions between Hippo pathway components also seem to be prevalent (Varelas, 2014) . For instance, loss of Mst1/2 in the liver results in increased YAP protein levels and reduced YAP phosphorylation as predicted by the model of canonical Hippo signaling; unexpectedly the phosphorylation state of LATS is unaltered in the absence of Mst1/2 (Zhou et al., 2009) . Therefore, the function and interaction of Hippo pathway components in each tissue can only be revealed by dissecting the Hippo pathway in a given tissue.
While the core components of the Hippo pathway are conserved, signals that activate the Hippo pathway and targets controlled by Hippo signaling are expected to be different in diverse tissues (Varelas, 2014) . In this regard, not only is the full spectrum of Hippo signaling effects on lung biology and pathology yet to be revealed, but the upstream regulators and downstream effectors of Hippo signaling in the lung are also largely unknown. A prerequisite to answering these important questions relies on establishing the function and interaction of individual Hippo pathway components in the lung. For instance, removal of Yap in the lung epithelium results in defective lung development (Mahoney et al., 2014) , supporting an essential role of Hippo signaling in controlling lung growth. However, this issue is complicated by a recent report in which the MST1/2 kinases were shown to regulate the transcription factor FOXA2 and not YAP during lung development. In this study, we employ multiple mouse Cre lines as well as lung cell lines to investigate the interactions between MST1/2 and YAP in controlling lung growth. Our findings indicate that the MST1/2-YAP axis is conserved in the lung. We surmise that variable efficiencies of the mouse Cre lines contribute to the seeming discrepancy in the regulatory relationship between MST1/2 and YAP in the lung.
Materials and methods

Animal husbandry
Shh-Cre [B6.Cg-Shh tm1(EGFP/cre)Cjt /J] and Nkx2.1-Cre [C57BL/6J-Tg (Nkx2-1-cre)2Sand/J] mice were obtained from Jackson Laboratory. Mst1 null and Mst2 floxed alleles were given to us by Dr. Yingzi Yang. Yap and Taz floxed alleles were provided by Dr. Eric Olson. The Institutional Animal Care and Use Committee at the University of California, San Francisco, approved all experiments performed in this study.
Histology and immunohistochemistry
Mouse embryos or adult mice were harvested at indicated time points and the embryos or lungs were fixed in 4% paraformaldehyde (PFA) in PBS at 4°C for 2 h. Lungs were embedded in paraffin and sectioned at 6 μm or embedded in OCT and sectioned at 10 μm. Histological analysis was performed as reported .
Histology and immunohistochemistry was performed following standard procedures. The following primary antibodies were used: rabbit anti-NKX2.1 (Epitomics, 1:100), mouse anti-p63 (Santa Cruz, 1:100), goat anti-Clara cell 10-kDa protein (CC10) (Santa Cruz, 1:200), mouse anti-acetylated (Ac)-tubulin (Sigma, 1:1000), rabbit anti-prosurfactant protein C (proSPC) (Millipore, 1:400), rabbit anti-mouse surfactant protein B (SPB) (Millipore, 1:200) , mouse anti-DC-LAMP (Beckman, 1:200), hamster anti-T1α (Developmental Studies Hybridoma Bank, 1:200), rabbit anti-aquaporin 5 (AQP5) (Abcam, 1:200) , mouse anti-Ki67 (BD Biosciences, 1:100), rabbit anti-phospho-Histone H3 (PH3) (Millipore, 1:200) , rat anti-E-Cadherin (Life Technologies, 1:500). Secondary antibodies and conjugates used were donkey anti-rabbit Alexa Fluor 488 or 594 (Life Technologies, 1:1,000), donkey anti-goat Alexa Fluor 488 or 594 (Life Technologies, 1:1,000), donkey anti-mouse Alexa Fluor 594 (Life Technologies, 1:1,000), donkey anti-rat Alexa Fluor 594 (Life Technologies, 1:1,000), and DAPI (Sigma, 1:10,000).
For biotinylated secondary antibodies (Jackson ImmunoResearch Laboratories, goat anti-hamster, 1:1000; goat anti-rabbit, 1:1000; donkey anti-goat, 1:1000; donkey anti-rat, 1:1000; and horse anti-mouse, 1:1000), the signal was detected using streptavidin-conjugated Alexa Fluor 488, 594, or 647 (Life Technologies, 1:1000) or HRP-conjugated streptavidin (Perkin-Elmer, 1:1000) in combination with either the chromogenic substrate DAB (Vector Laboratories) or fluorogenic substrate Alexa Fluor 488 tyramide (Perkin-Elmer, 1:200, TSA kit).
For PAS staining, paraffin sections were deparaffinized, oxidized in 0.5% periodic acid solution for 5 min and washed with distilled water. The sections were subsequently placed in the Schiff reagent for 15 min, washed in tap water for 5 min and counterstained with Mayer's hematoxylin.
For BrdU or EdU incorporation, mice were injected with 1-2 mg of BrdU or EdU solution and lungs were collected 2-3 h following BrdU or EdU injection. BrdU staining was performed using the BrdU Staining Kit (Life Technologies). EdU staining was performed using the Click-iT s EdU Alexa Fluor 488 Imaging Kit (Life Technologies) . For TUNEL analysis, paraffin sections were deparaffinized and antigen retrieved. The sections were permeablized in PBS/0.5% Triton-X100 for 15 min, blocked in 3% BSA for 1 h at room temperature and incubated with rabbit anti-NKX2.1 antibodies (Epitomics) at 4°C overnight. Anti-rabbit Alexa Fluor 594 secondary antibodies (Molecular Probes) were added to the TUNEL reaction mix, which was prepared by diluting 1 part of Enzyme Solution in 9 parts of Label Solution from the In Situ Cell Death Detection Kit (Roche). The sections were incubated with the secondary antibody/TUNEL reaction mix for 1 h at 37°C, washed in PBS for three times, incubated with DAPI for 5 min and mounted in Vectashield for microscopy.
Fluorescent images were acquired using a SPOT 2.3 CCD camera connected to a Nikon E1000 epifluorescence microscope. Confocal images were captured on a Leica laser-scanning confocal microscope. Adjustment of red/green/blue histograms and channel merges were performed using a SPOT Advanced software or ImageJ.
qPCR analysis
Total RNA was extracted from lung tissues using Trizol (Invitrogen) and subsequently reverse-transcribed using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative PCR (qPCR) was carried out on the ABI Prism 7900HT Sequence Detection System. The following primers for mouse genes were used: Gapdh F: AGGTTGTCTCCTGCGACTTCA, Gapdh R: CCAGGAAATGAGCTTGA-CAAAGTT; Ctgf F: CTCCACCCGAGTTACCAATG, Ctgf R: TGGCGATTT-TAGGTGTCCG; Ajuba F: GGTATCTATGGGCAGAGCAATG, Ajuba R: CAG-TAGACAGAGCCATTGACG; Cyr61 F: GTGAAGTGCGTCCTTGTGGACA, Cyr61 R: CTTGACACTGGAGCATCCTGCA; Foxa2 F: CGGGACTTAACTG-TAACGGG, Foxa2 R: TCATGTTGCTCACGGAAGAG; Sftpc (SPC) F: 
Western blot analysis
Embryonic lung tissues were homogenized in RIPA buffer supplemented with Complete Protease Inhibitor Cocktail tablets (Roche) and PhosSTOP Phosphatase Inhibitor Cocktail tablets (Roche). The lysates were cleared and analyzed by Western blot as previously described .
The following primary antibodies were used: rabbit anti-YAP (Cell Signaling, 1:500), rabbit anti-phospho-YAP (Cell Signaling, 1:1000), rabbit anti-LATS (Cell Signaling, 1:1000), rabbit antiphospho-LATS (Cell Signaling, 1:1000), rabbit anti-MST1 (Cell Signaling, 1:500), rabbit anti-MST2 (Cell Signaling, 1:1000), goat anti-MST1/2 (Santa Cruz 1:100), goat anti-CTGF (Santa Cruz, 1:200).
Genome-wide identification of conserved TEAD-binding sites in gene promoters
Searching for putative TEAD-binding sites (GGAATG) on mouse gene promoters ( À 500 to 0; transcription start as þ1) was performed using the Regulatory Sequence Analysis Tools (RSAT) (http://rsat.ulb.ac.be/rsat/) and implemented with the pattern matching tool. The conservation of the cis-regulatory elements identified was assessed using the "Conservation" track from the UCSC browser (http://genome.ucsc.edu/).
shRNA-mediated knockdown in cell lines
shRNAs were designed using pSicOligomaker (Reynolds et al., 2004) and oligonucleotides encoding shRNAs were cloned into the pLentiLox3.7 vector. Lentiviruses were produced as described ). A549 and MLE 12 cells at 50% confluence were transduced with lentiviruses supplemented with 8 μg/ml polybrene. Upon reaching confluence, the cells were collected for RNA and protein extraction. The following 19-mer target sequences were used for shRNA-mediated knockdown: GTACAAGGCTAT-TCATAAA and GCAGGTCAACTTACAGATA for mouse Mst1 (NM_021420); GTCAAGTGGTTGCAATTAA and GTACACACCTAGA-TAAATT for mouse Mst2 (NM_019635); GGAGAAGTTTACTACATAA and GTAGTGTGATAGCAGAATA for mouse Yap (NM_009534); GCCAGATTGTTGCTATTAA for human MST1 (NM_006282); GTCA-AGTTGTCGCAATTAA for human MST2 (NM_006281); GAAG-TAGTTTAGTGTTCTA for human YAP (NM_006106).
Results
Inactivation of Mst1/2 by Nkx2.1-Cre in mice leads to postnatal lethality and lung defects
We took advantage of a null allele of Mst1 (denoted Mst1 À ) and a conditional (floxed) allele of Mst2 (Mst2f) (Song et al., 2010) to study the function of Mst1/2 in the lung. As a first step, we utilized Nkx2.1-Cre (Xu et al., 2008) to inactivate Mst2 in the lung epithelium since Nkx2.1 is expressed in all lung endodermal cells. We
transgenic allele of Nkx2.1-Cre) were viable and fertile without apparent gross abnormalities (Fig. 1A , B, E, F). By contrast,
Cre/Cre mice (carrying two alleles of Nkx2.1-Cre) exhibited various phenotypes postnatally (Fig. 1A , C, E, G). At birth, they cannot be distinguished from their wild-type littermates by external morphology but subsequently became visibly smaller in size and appeared emaciated. These mice died at various time points after birth; most of them perished before they reached 3 weeks of age although a few survived beyond that ( Fig. 1I , J, K). These findings are largely similar to reports on Mst1
Mst2
À / À mice that also carry Nkx2.1-Cre . In that study, a conditional allele of Mst1 (Mst1 f ) (Katagiri et al., 2009) and a null allele of Mst2 (Mst2 À ) (Oh et al., 2009 ) were utilized to assess the functional consequence of Mst1/2 removal in the lung. As expected from their reduced postnatal survival, Mst1 À / À ; Mst2 f/f ; Nkx2.1 Cre/Cre mice displayed more severe lung defects than
Cre/ þ mice in our study (Fig. 1B, C, F, G) . Upon gross examination, we noticed regions of lungs at the upper lobes that lost the normal color and architecture in both
Cre/Cre mice ( Fig. 1B, C ; Fig. S1 ). These affected regions were more extensive in Mst1
significantly larger number of extra lung cells were present in ; Shh Cre/ þ mice at 16.5 dpc. It is possible that increased cell proliferation and phenotypic consequences only become apparent after 16.5 dpc. Scale bar¼ 50 μm.
*Po 0.05; **Po 0.01; NS, not significant (unpaired Student's t-test). Elimination of Mst1/2 by Shh-Cre in mice results in neonatal lethality and more severe lung phenotypes
In other studies that utilize epithelial mouse Cre lines to inactivate conditional alleles, we noticed that Nkx2.1-Cre (Xu et al., 2008) was less efficient than Shh-Cre (Harfe et al., 2004) in converting a conditional allele into a null allele. We wondered whether the lung defects in Mst1 À / À ; Mst2 f/f ; Nkx2.1 Cre/Cre mice represented a partial loss of Mst1/2 function in the lung epithelium and lung defects associated with complete elimination of Mst1/2 function have not been revealed. To address this issue, we employed Shh-Cre, which seems to exhibit a high efficiency in the lung epithelium, to remove Mst1/2 in the lung. Taking a similar approach, we generated Mst1
Cre/ þ mice (carrying one knock-in allele of Shh-Cre). Of note,
; Shh Cre/Cre mice (carrying two alleles of Shh-Cre)
exhibited the classical Hedgehog phenotypes, including cyclopia, holoprosencephaly and limb and lung defects, due to disruption of the Shh locus and these animals died at various time points during embryonic development as previously reported (Chiang et al., 1996) . Mst1 À / À ; Mst2 f/f ; Shh Cre/ þ mice died soon after birth although they could not be distinguished from their wild-type littermates by external morphology. The dying pups were gasping for air, suggesting that they suffered from respiratory distress. Inspection of their lungs revealed only small pockets of air, indicating a failure of lung expansion after birth that resulted in neonatal lethality (Fig. 1A, D) . On rare occasions, some Mst1
; Shh Cre/ þ mice ( $ 5%) escaped neonatal lethality. These escapers could die within three weeks of age but most of them reached adulthood although some of these adult escapers still displayed varying degrees of lung defects (Fig. 1I, L) . In contrast to the postnatal lethality in Mst1
mice suggest a more severe lung defect in these animals ( Fig. 1E-H ). This confirms our speculation that efficient removal of Mst1/2 using Shh-Cre is required to uncover the phenotypes associated with a more complete loss of Mst1/2 function in the lung epithelium. Consistent with this, analysis of MST2 protein from Mst1 À / À ;
Mst2 f/f
; Shh Cre/ þ lungs at 16.5 and 18.5 days post-coitus (dpc) revealed significantly reduced MST2 protein levels (Fig. S2) . The residual MST2 protein likely comes from the lung mesenchyme since Shh-Cre is not expressed in the mesenchymal compartment. Importantly, MST2 protein levels were reduced to a lower level in
Cre/Cre lungs (Fig. S2) , supporting the notion that Shh-Cre is more efficient than Nkx2.1-Cre in converting Mst2 f to a null allele.
Analysis of Mst1
Nkx2.1 Cre/Cre lungs reveals increased cell proliferation and disrupted lung cell differentiation
We performed a detailed phenotypic analysis of lungs from
Shh
Cre/ þ lungs at 18.5 dpc or postnatal day 0 (P0) had reduced airway space ( Fig. 1D, H; Fig. S3 ). In addition, the mutant lungs had a more compact appearance likely due to the presence of more lung cells. Compared with
lungs appeared denser and possessed a larger number of lung cells ( Fig. 1E-H) . We determined the rate of cell proliferation in Mst1
Cre/ þ lungs by BrdU or EdU incorporation. Epithelial cells were distinguished by staining with E-cadherin antibody (Fig. 2Y, Z) . We found that the number of BrdU þ or EdU þ cells was increased in
; Shh Cre/ þ lungs at 18.5 dpc ( Fig. 2A') . Interestingly, expression of cell cycle regulators, such as Mycn (N-myc) and Ccnd2 (cyclin D2) was elevated in Mst1
; Shh Cre/ þ lungs (Fig. 3A) . These results suggest that increased cell proliferation in the absence of Mst1/2 could account for the increased cell number and denser lung morphology. In support of this notion, in many bronchioles, the simple columnar epithelium in wild-type lungs (Fig. 2I ) was replaced by pseudostratified epithelium in Mst1
; Shh Cre/ þ lungs (Fig. 2L ).
Expression of cell cycle regulators was also increased in Mst1
; Nkx2.1 Cre/Cre lungs (Fig. 3B) , consistent with the presence of extra lung cells. By contrast, the rate of cell death was not significantly altered in the absence of Mst1/2 (Fig. S4) .
The lung epithelial cells were marked by NKX2.1 in Mst1
; Shh Cre/ þ lungs in a pattern similar to that of control lungs at 18.5 dpc, suggesting that the lung epithelial cell fate is unaffected in the absence of Mst1/2 (Fig. S4) Fig. 2A-P; Fig. S3 ); however, Clara cells and ciliated cells were relatively sparse (Fig. 2D , J, Q; Fig. S3 ). This is consistent with reduced levels of CC10 (Clara cell) and Foxj1
; Shh Cre/ þ lungs (Fig. 3C ). (Fig. 3D) . By contrast, changes in lung epithelial cell number were not apparent in Mst1
Cre/ þ lungs ( Fig. 2T-V) , correlated with their mild lung phenotypes and lack of postnatal lethality. These results indicate that while loss of Mst1/2 did not interfere with lobation or branching, the correct number of lung epithelial cells failed to be produced. This likely reflects partial disruption of coordinated lung epithelial cell proliferation and differentiation in the absence of MST1/2 activity.
Hippo target genes are upregulated in Mst1
À / À ; Mst2 To characterize the molecular defects in Mst1/2 mutant lungs, we asked whether expression of YAP targets was affected in the absence of Mst1/2. We extracted RNA from Mst1 À / À ; Mst2 f/f ; Shh Cre/ þ lungs at 16.5 and 18.5 dpc and examined the expression of Hippo targets by qPCR analysis and Western blotting. We found that mRNA levels of well-documented YAP targets, such as Ctgf (connective tissue growth factor, Ccn2) and Cyr61 (cysteine rich protein 61, CCN1) (Chan et al., 2011; Zhang et al., 2009; Zhao et al., 2008) , were significantly elevated in the mutant lungs (Fig. 3E) . CTGF protein levels were also increased in Mst1
Shh
Cre/ þ lungs at 16.5 and 18.5 dpc ( Fig. 3G; Fig. S5 ). These results provide strong evidence to support increased YAP activity in Mst1/ 2-deficient lungs.
To confirm increased YAP activity in the absence of Mst1/2, we searched for additional YAP target genes in the lung. We conducted a genome-wide promoter analysis using the Regulatory Sequence Analysis Tools (RSAT) to identify genes that contain conserved TEADbinding sites in their promoters. Candidates were further tested in a mouse lung epithelial cell line, MLE 12 (Wikenheiser et al., 1993) , for induced expression by YAP
S5A
, an active form of YAP in which five LATS phosphorylation sites are removed (Zhao et al., 2007 ; Shh Cre/ þ lungs (Fig. 3E) . ; Shh Cre/ þ lungs at 16.5 and 18.5 dpc and studied the protein levels of total YAP and phospho-YAP (S127) by Western blotting. Indeed, loss of Mst1/2 was accompanied by a relative decrease in phospho-YAP protein levels (normalized to total YAP) ( Fig. 3G; Fig. S5 ). This is consistent with a model in which elimination of Mst1/2 relieves YAP protein phosphorylation and degradation in the cytoplasm. Increased protein levels of active (non-phosphorylated) YAP in the absence of Mst1/2 could lead to upregulation of YAP target gene expression. We noticed that in 
Immunostaining of lung sections collected from control and Mst1
Shh Cre/ þ mice at P4 and P24. Lung cell types appeared to be properly specified in Mst1 In the canonical Hippo pathway, LATS has been proposed to mediate the function of MST1/2 in controlling YAP activity. In this model, the MST1/2 kinases phosphorylate the LATS kinase, which in turn phosphorylates YAP. This linear pathway seems to be highly context-dependent and variations have been found in some tissues or cell lines studied (Zhou et al., 2009 ). To test whether LATS relays MST1/2 activity in the lung, we examined the protein levels of total LATS and phospho-LATS in Mst1/2-deficient lungs by Western blotting. Both total LATS and phospho-LATS protein levels were largely unaltered in Mst1 À /À ; Mst2 f/f ; Shh Cre/ þ lungs at either 16.5 or 18.5 dpc
; Nkx2.1 Cre/Cre lungs at P2 (Fig. 3G, H and data not shown). We speculate that minor changes in epithelial LATS protein phosphorylation caused by loss of Mst1/2 were masked since LATS from the whole lung was analyzed. However, we cannot exclude the possibility that LATS controls YAP activity but LATS activation is not correlated with changes in its protein levels or phosphorylation states in the lung. Finally, MST1/2 may exploit a player other than LATS to modify YAP activity during lung growth. Removal of one allele of Yap or one copy of both Yap and Taz can rescue neonatal lethality and lung defects induced by loss of Mst1/2 by Shh-Cre in the lung epithelium
To provide a more definitive answer to the regulatory relationship between MST1/2 and YAP in the lung, we performed genetic rescue experiments. We reasoned that if the neonatal lethality and lung phenotypes observed in Mst1
Shh
Cre/ þ mice are due to increased YAP and/or TAZ function, reduction of Yap/Taz gene dosage should normalize YAP/TAZ activity and restore proper Hippo signaling. To this end, we employed conditional alleles of Yap (Yap f ) (Xin et al., 2011) and Taz (Taz f ) (Xin et al., 2013) and set up crosses to obtain Mst1 À / À ;
and Taz f into null alleles and reduce YAP/TAZ activity. Indeed, no neonatal lethality was observed in Mst1
Shh Cre/ þ mice and they survived to adulthood without obvious lung phenotypes compared to their wild-type littermates ( Fig. 4A-P) . No apparent defects in lung epithelial cell specification were detected in these animals ( Fig. 4A-P) . This suggests that the activity of the nuclear effectors of MST1/2 (i.e. YAP/TAZ) is reduced to the extent that expression of Hippo target genes are no longer upregulated to disrupt lung development. We also tested whether removing one copy of Yap is sufficient to rescue the neonatal lethality in the absence of Mst1/2. Somewhat surprisingly, similar to
Cre/ þ mice also survived to adulthood without discernable lung phenotypes compared to their wild-type littermates ( Fig. 5A-P) . This is consistent with the model in which YAP plays a more dominant role than TAZ in the Hippo pathway during lung development. Thus, in the absence of Mst1/2, removal of one copy of Yap reduces YAP activity to the level that enables proper Hippo signaling and lung development. Taken together, our findings provide strong genetic evidence to support a conserved MST1/2-YAP/TAZ axis in controlling lung development.
Knockdown of Mst1/2 in alveolar lung cell lines leads to elevated Yap target and reduced alveolar marker expression, which can be restored by inactivating Yap
To complement the genetic studies, we employed cell-based assays and used A549 (Lieber et al., 1976) and MLE 12 cells (Wikenheiser et al., 1993) to further probe the relationship between MST1/2 and YAP. The human A549 lung cell line is widely used as an in vitro model for alveolar type II cells while the mouse MLE 12 lung cell line maintains properties of distal respiratory epithelial cells and expresses surfactant proteins. A549 and MLE 12 cells were transduced with lentiviruses that carry shRNA against Mst1/2 (Fig. 6A, B) . Knockdown of Mst1/2 was assessed by Western blotting. We found that reduced Mst1/2 expression in cultured cells led to increased expression of YAP targets such as CTGF (Fig. 6B) . Interestingly, expression of alveolar markers such as SPB/SPC was reduced when Mst1/2 were inactivated in lung cells (Fig. 6A) , similar to findings obtained in Mst1/2 deficient lungs (Fig. 3C, D) . Importantly, elevated YAP target and reduced SPB/SPC expression was abolished when Yap was simultaneously knocked down in conjunction with Mst1/2 (Fig. 6A, B) . These results are consistent with negative regulation of YAP targets by MST1/2 in lung cell lines and further support a conserved MST1/2-YAP axis during lung growth (Fig. 7) .
Discussion
Our studies clarify the regulatory relationship between MST1/2 and YAP during lung growth and development. Through a combination of phenotypic analysis, genetic epistasis, molecular characterization and cell-based assays, we define a conserved MST1/2-YAP axis in regulating lung growth. These results also establish the foundation for future investigations to uncover the genetic and molecular interactions of Hippo pathway components during lung development and homeostasis and in lung diseases.
Control of YAP activity by MST1/2 appears to be contextdependent (Varelas, 2014) . In the liver, pancreas, heart and nervous system, a classical MST1/2-YAP axis mediates critical aspects of Hippo signaling. Our work shows that a similar MST1/2-YAP axis also operates during lung growth. By contrast, MST1/2 are found to function independently of YAP in the skin (Schlegelmilch et al., 2011) and kidney (Reginensi et al., 2013) and in mouse embryonic fibroblasts (MEFs) (Zhou et al., 2009) . This is in contrast to other major signaling pathways, which utilize a common signaling cascade in diverse tissues and cell lines. This unique aspect of Hippo signaling could reflect the distinct signal input and integration that Hippo signaling needs to accommodate in a given tissue. As a result, MST1/2 and YAP may be subject to differential regulation in some tissues and no longer exhibit a direct regulatory relationship.
Our analysis of Mst1/2-deficient lungs demonstrates upregulation of YAP targets, including the well-established targets, Ctgf and Cyr61, and new YAP targets, Ajuba, Lamc2 and Prkci, in the absence of Mst1/2. This is associated with a relative reduction in phospho-YAP protein levels. Together, these findings provide strong evidence to support negative regulation of YAP by MST1/2. Consistent with the expected difference in Cre activity, MST2 protein reduction is more complete and upregulation of YAP targets is more pronounced in lungs in which Mst1/2 are removed by Shh-Cre than those induced by Nkx2.1-Cre in our investigation. Of note, a recent study Mst1/2 function in the lung requires additional studies. It is interesting to note that removal of Foxa2 in the lung epithelium affects alveolarization but not branching morphogenesis (Wan et al., 2004) while epithelial deletion of both Foxa1 and Foxa2 inhibits branching morphogenesis (Wan et al., 2005) . While a relative reduction in phospho-YAP protein levels was observed in Mst1/2-deficient lungs, variations in YAP and phospho-YAP protein levels were noted in different litters of mice. This could be caused by variable Cre activity but it could also be due to additional YAP regulators other than MST1/2 in the lung. Moreover, YAP from both lung epithelium and mesenchyme was detected in our assays and this may have masked small changes in YAP protein levels in the epithelium. While isolated lung epithelial cells would provide a more accurate assessment of changes in YAP protein levels, it is unclear how manipulation of the lung epithelium such as disruption of cell junctions for cell isolation and sorting would affect YAP protein expression. In contrast to altered YAP protein levels in Mst1/2-deficient lungs, protein levels of phospho-LATS seem to be unaltered. It is very likely that a minor shift in epithelial LATS protein levels was obscured in assays using the whole lung as described above. Nevertheless, we cannot rule out the possibility that LATS may control YAP activity but LATS activation is not correlated with changes in its protein levels or phosphorylation states in the lung. Moreover, MST1/2 may employ kinases other than LATS to modify YAP in the lung. The lack of a linear relationship between MST1/2, LATS and YAP has been reported in other tissues (such as the liver) (Zhou et al., 2009) . These findings highlight the context-dependent interactions between Hippo pathway components. They also underscore the importance of studying Hippo signaling in tissues and organs to uncover its function in a physiological setting.
Our analysis of Mst1 ) would display phenotypes similar to those in Mst1/2-deficient lungs. Furthermore, genetic analysis of the lung phenotypes in Lats mutant mice in conjunction with double mutant analysis would shed light on the relationship between Mst1/2, Lats and Yap in the lung. These genetic studies will complement cell-based assays in delineating the interactions of Hippo pathway components in the respiratory system.
Nkx2.1-Cre is presumably expressed from the earliest time point of lung development and Nkx2.1-Cre can label most, if not all, lung epithelial cells . It is thus somewhat surprising that Nkx2.1-Cre is less efficient in removing Mst1/2 in lung epithelium than Shh-Cre. We speculate that this could be due to the expression levels of Nkx2.1-Cre. Indeed, mice carrying two alleles of Nkx2.1-Cre display more severe lung phenotypes caused by Mst1/2 deletion than those with only one Nkx2.1-Cre allele. Moreover, Nkx2.1-Cre may be expressed at higher levels at the upper lung lobes or these regions are more sensitive to loss of Mst1/2 activity since the lung phenotypes are more severe in these areas. Even if the cumulative effects of Nkx2.1-Cre activity eventually result in apparent removal of Mst1/2 at birth, residual Mst1/2 function during lung development could be sufficient to support In these studies, Mst1/2 were knocked down individually or in combination with Yap inactivation by shRNA as indicated. shRNA against GFP served as a control. Knockdown of Mst1/2 resulted in reduced expression of SPB/SPC (alveolar type II cell markers), consistent with findings in Mst1/2-deficient lungs. Inactivation of Mst1/2 also led to increased CTGF (YAP target) expression and reduced levels of phospho-YAP, both of which are associated with increased YAP activity. Such alteration in gene expression was restored when Yap was simultaneously knocked down by shRNA in conjunction with Mst1/2. These results further support conclusions from analysis of Mst1/2 mutant lungs. Tubulin was used as the loading control. substantial lung growth. Finally, we anticipate that Nkx2.1-Cre would be less efficient in general than Shh-Cre in converting a conditional allele to a null allele in the lung epithelium. It is unclear whether this is due to mosaic expression from transgenic mouse lines or it reflects the expression levels of individual promoter activity. A combined use of different epithelial Cre lines thus offers a unique opportunity to reveal a spectrum of phenotypes and uncover the molecular basis of these defects.
Both Nkx2. Loss of Mst1/2 leads to increased YAP target gene expression. How the activation of YAP targets controls diverse aspects of lung cell behavior has not been elucidated. Conversely, the molecular mechanisms by which loss of YAP affects lung branching morphogenesis remain unclear. YAP targets likely mediate central aspects of YAP activity. In this regard, the newly identified YAP targets, Lamc2 and Prkci, are potential candidates to link Hippo signaling to cellular microenvironment. It is uncertain how increased Hippo signaling activity disrupts the normal process of lung cell proliferation/differentiation and compromises the production of a proper number of distinct lung cell types. Perhaps, accelerated cell proliferation and perturbed cell differentiation caused by loss of Mst1/2 collectively result in an imbalance of cell type production. Thus, the number of some lung cell types is significantly reduced. To gain further insight into these important issues requires future studies to trace the lineage and fates of Mst1/ 2-deficient epithelial cells during lung development and to identify genes and pathways perturbed due to the disruption of Mst1/2. Since MST1/2 likely control a plethora of targets, it is likely that multiple YAP targets rather than one target would mediate the effects of MST1/2. Moreover, MST1/2 and YAP may function in a complex network in tissues; Mst1/2 regulate genes other than Yap and conversely YAP receives signals other than MST1/2. Uncovering the functions of genes and pathways regulated by MST1/2 and YAP during lung development will increase our mechanistic understanding of how Hippo signaling controls lung growth.
Many genes and pathways that control lung development have been identified (Borok et al., 2011; Dobbs et al., 2010; Domyan and Sun, 2011; Hardie et al., 2010; Herriges and Morrisey, 2014; Kotton, 2012; Morrisey et al., 2013; Ornitz and Yin, 2012; Shi et al., 2009; Warburton et al., 2010) . Whether and how these major pathways participate in lung growth control requires additional studies. Since lung growth is a tightly controlled process, we speculate that a master regulatory pathway is required to integrate diverse inputs and coordinate a multitude of cellular behaviors. In this regard, Hippo signaling is a strong candidate in transducing external signals into organized cellular changes. Our studies suggest interactions between MST and YAP in the lung. Control of YAP/ TAZ activity by MST1/2 regulates many aspects of cellular behavior during lung development. YAP plays a more dominant role than TAZ in Hippo signaling. In this model, loss of MST1/2 shifts YAP toward the non-phosphorylated state, which is no longer sequestered in the cytoplasm and also free from degradation. Instead, nonphosphorylated YAP is enriched in the nucleus to activate YAP targets, leading to cell proliferation and fate determination and other changes in cellular properties. This canonical relationship between MST and YAP is observed in many tissues. The mediator of Hippo signaling between MST1/2 and YAP in the lung could be LATS (another conserved feature of the Hippo pathway) or some other unknown kinases. Factors that activate MST1/2 have been inferred from cell-based studies but signals that control MST activity in the lung remain unclear.
